AMG157
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 98 | 好酸球性消化管疾患 | 11 |
98. 好酸球性消化管疾患
臨床試験数 : 214 / 薬物数 : 171 - (DrugBank : 46) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 142
Showing 1 to 10 of 11 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2022-001294-31-DE (EUCTR) | 14/03/202320230314 | 07/10/202220221007 | Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republi ... | ||
| 2 | EUCTR2022-001294-31-NL (EUCTR) | 31/01/202320230131 | 24/10/202220221024 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Netherlands;Austria;Sweden;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Netherlands;Austria;Swede ... | ||
| 3 | EUCTR2022-001294-31-FI (EUCTR) | 20/01/202320230120 | 05/10/202220221005 | A study to investigate changes in symptoms and esophageal histology withtezepelumab compared with placebo in patients aged 12 to 80 years oldwith eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology withtezepelumab compared with pl ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Swede ... | ||
| 4 | EUCTR2022-001294-31-BE (EUCTR) | 09/01/202320230109 | 11/10/202220221011 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in Patients aged 12 to 80 years old with Eosinophilic Esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republi ... | ||
| 5 | EUCTR2022-001294-31-SK (EUCTR) | 21/12/202220221221 | 19/09/202220220919 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Slovakia;Israel;Australia;Germany United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Swede ... | ||
| 6 | EUCTR2022-001294-31-NO (EUCTR) | 06/12/202220221206 | 13/09/202220220913 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republi ... | ||
| 7 | EUCTR2022-001294-31-IT (EUCTR) | 01/12/202220221201 | 16/11/202220221116 | Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens andcharacterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab APFS Product Code: [MEDI9929 anti-TSLP mAb (AMG157)] INN or Proposed INN: Tezepelumab Other descriptive name: AMG157 Product Name: Tezepelumab APFS Product Code: [MEDI9929 anti-TSLP mAb (AMG157)] INN or Proposed INN: Te ... | ASTRAZENECA AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Sweden;Netherlands;Czech Republi ... | ||
| 8 | EUCTR2022-001294-31-DK (EUCTR) | 22/11/202220221122 | 04/10/202220221004 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republic;Belgium;Norway;China;Finland;Denmark;Brazil;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republi ... | ||
| 9 | EUCTR2022-001294-31-SE (EUCTR) | 09/11/202220221109 | 15/09/202220220915 | A study to investigate changes in symptoms and esophageal histology withtezepelumab compared with placebo in patients aged 12 to 80 years oldwith eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology withtezepelumab compared with pl ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Sweden;Austria;Netherlands;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;Spain;New Zealand;Greece;Canada;Sweden;Austria;Netherlands;Czech Republi ... | ||
| 10 | EUCTR2022-001294-31-AT (EUCTR) | 00000000 | 22/12/202220221222 | A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years old with eosinophilic esophagitis A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with p ... | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of ... | Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune respo ... | Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: Tezepelumab Other descriptive name: AMG 157 Product Name: Tezepelumab via APFS Product Code: MEDI9929 anti-TSLP mAb (AMG157) INN or Proposed INN: ... | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 360 | Phase 3 | United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Sweden;Czech Republic;Belgium;Norway;China;Finland;Brazil;Denmark;Italy;Israel;Slovakia;Australia;Germany United States;Czechia;Japan;United Kingdom;Spain;New Zealand;Greece;Canada;Austria;Netherlands;Swede ... |